Menveo

Menveo is a vaccine used to prevent meningitis. 

Menveo is a vaccine used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.

Menveo is approved for use in persons 2 months through 55 years of age.

Menveo does not prevent N. meningitidis serogroup B infections.

• Novartis Vaccines and Diagnostics Limited

Side effects reported with Menveo in persons aged 2 months old include:

• tenderness and redness at the injection site
• irritability
• sleepiness
• persistent crying
• change in eating habits
• vomiting
• diarrhea

Side effects reported with Menveo in persons aged 7 months to 23 months old include:

• tenderness and redness at the injection site
• irritability
• sleepiness
• persistent crying
• change in eating habits
• diarrhea

Side effects reported with Menveo in persons aged 2 through 10 years old include:

• pain and redness at the injection site
• irritability
• sleepiness
• a general feeling of discomfort, illness, or uneasiness (malaise)
• headache

Side effects reported with Menveo in adolescents and adults include:

Tell your healthcare provider if you have any new or unusual symptoms after you receive Menveo. For a complete list of side effects, ask your health care provider.

To report suspected adverse reactions, contact VAERS at 1-800- 822-7967 or http://vaers.hhs.gov.

Tell your doctor about all the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Especially tell your doctor if you take or have received:

• immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids
• other vaccines

This is not a complete list of Menveo drug interactions. Ask your doctor or pharmacist for more information. 

Serious side effects have been reported with Menveo including the following:

• Allergic reactions. Tell your healthcare provider about any signs or symptoms of allergic reactions, which include the following:
  • chest pain
  • swelling of the face, eyes, lips, tongue, arms, or legs
  • difficulty breathing or swallowing
  • rash
• Fainting. Fainting can occur in association with administration of Menveo.
• Guillain-Barré Syndrome. Those who have been diagnosed with Guillain-Barré Syndrome, may be at a higher risk of Guillain-Barré Syndrome after receiving Menveo.
• Altered immunocompetence. If Menveo is administered to immunocompromised persons, including persons receiving immunosuppressive therapy, the expected immune response may not be obtained.
• Premature infants may temporarily stop breathing. Breathing issues have been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including Menveo, to an infant born prematurely should be based on consideration of the individual infant's medical status, and the potential benefits and possible risks of vaccination.

Do not get Menveo if you or your child had a severe allergic reaction (e.g., anaphylaxis) after a previous dose of Menveo, any component of this vaccine, or any other CRM197, diphtheria toxoid or meningococcal-containing vaccine.

Medications can interact with certain foods. In some cases, this may be harmful and your doctor may advise you to avoid certain foods. In the case of Menveo, there are no specific foods that you must exclude from your diet when receiving this medication. 

Tell your healthcare provider if you or your child:

• had a severe allergic reaction (e.g., anaphylaxis) after a previous dose of Menveo, any component of this vaccine, or any other CRM197, diphtheria toxoid or meningococcal-containing vaccine
• are pregnant or plan to become pregnant
• are breastfeeding
• have received other vaccines

Tell you doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. 

Tell your doctor if you are pregnant or plan to become pregnant.

The FDA categorizes medications based on safety for use during pregnancy. Five categories - A, B, C, D, and X, are used to classify the possible risks to an unborn baby when a medication is taken during pregnancy.

Menveo falls into category B. There are no well done studies that have been done in animals with Menveo. Menveo should be given to a pregnant woman only if clearly needed. 

Tell your doctor is you are breastfeeding or plan to breastfeed. 

It is not known if Menveo crosses into human milk. Because some vaccines can cross into human milk and because of the possibility for serious adverse reactions in nursing infants with use of this vaccine, caution should be taken when Menveo is given to a nursing woman. 

Menveo is given by a healthcare provider as a shot into the muscle in the thigh or upper arm. 

Menveo is preferably given into the the thigh in infants or into the upper arm in toddlers, adolescents and adults.

Menveo is given by a healthcare provider as a shot into the muscle in the thigh or upper arm. 

Menveo is administered by a healthcare provider in a medical setting. It is unlikely that an overdose will occur in this setting. However, if overdoes is suspected, seek emergency medical attention.